food-science-dubai-2019-keynote

2 / 14

allied
academies
Page 9
Notes:
Journal of Food Science and Nutrition | Volume 2
December 09-10, 2019 | Dubai, UAE
Nutrition, Food Science and Technology
8th International Conference on
J Food Sci Nutr, Volume:2
Recent epidemiological studies reveal that 35 % of cancer
initiation may be related to food, lack of nutrition and
sedate lifestyle. However, it is hard to connect directly which
ingredient of which food and how long it takes to develop
cancer. Although Vitamins including Vitamin E have several
favourable health related properties, translating them to
therapeutic dose using food matrix is hard which necessitates
new formulation, supplements and delivery through a novel
drug releasing technology. Chemotherapy, despite widely
used for treatment of cancer is nonspecific resulting in the
collateral damage to normal cells. Vitamin E is an antioxidant
which can help repair the DNA damage to normal cells
induced by chemotherapy. In order to deliver the optimum
dose, Vitamin E was esterified with pegylation to make it
water soluble and administered orally. The esterase enzyme
available in the body hydrolyses the ester bond to release
VitaminEtoreachthetherapeuticlevel.Ontheotherhand,the
same Vitamin E was derivatized using a dipeptide linker which
is cleaved by tumour specific enzyme which is overexpressed
by cancer cells. The technology is often referred to as “A Priori
Activation of Apoptosis Pathways of Tumour” AAAPT. Cancer
cells are known for desensitizing themselves to intervention.
AAAPT identified several dysregulated pathways to sensitize
those cells which do not respond to chemotherapy. Targeted
tumour sensitizing technology enables to expand the
therapeutic index of current FDA approved chemotherapy
by lowering the therapeutic dose without reducing efficacy.
Optimization of drug design using Vitamin E resulted in
reducing cardiotoxicity of the current chemotherapy drugs.
Speaker Biography
Raghu Pandurangi started his scientific career Ph.D. in spectroscopy followed
by post-doctoral training at Radiology and Internal medicine, University of
Missouri, Columbia where he remained as a faculty for 10 years teaching
radiopharmaceuticals and chemistry and guided graduate students with
funds from American Heart Association and NIH funding. He was a principle
investigator inScheringAG,Germanywherehedirectedand involved in2FDA
approveddrugs(AccuTectandNeoTect).Hewasateam leaderatMallinckrodt
directing apoptosis imaging. He became an entrepreneur in 2013 inventing
AAAPT technology for improving FDA approved drugs. Currently, he is the
Founder, President and CSO of Sci-Engi-Medco Solutions (SEMCO) and
Amplexi-LLC, recipient of several NIH grants and awards. He also an ardent
percussionist (Tabla) and VP for Anu-Rag School of Music, A non-profit
organization headed by his wife Guru Sandhya Pandurangi.
e:
Raghu Pandurangi
SSci-Engi-Medco Solutions Inc (SEMCO), USA
Role of Vitamin E and Vitamin E derivatives in Cancer treatment and
in offsetting toxicity by Chemotherapy